Nivolumab biosimilar (Shandong Boan Biotechnology)

纳武利尤单抗生物类似药 (山东博安生物)

Report date: 2024/02/26 16:43:32

Base Information

Drug NameNivolumab biosimilar (Shandong Boan Biotechnology)
Drug Alias NameOpdivo biosimilar (Shandong Boan Biotechnology)LY-01015BA-1104
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgrammed cell death protein 1 inhibitors
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsUrinary Bladder Neoplasms +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShandong Boan Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLuye Pharma Group LtdShandong Boan Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsUrinary Bladder Neoplasms +[12] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XC17
Related LinksWikipediaDrugBankKEGG